DK2885641T3 - Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension - Google Patents
Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertensionInfo
- Publication number
- DK2885641T3 DK2885641T3 DK13830006.6T DK13830006T DK2885641T3 DK 2885641 T3 DK2885641 T3 DK 2885641T3 DK 13830006 T DK13830006 T DK 13830006T DK 2885641 T3 DK2885641 T3 DK 2885641T3
- Authority
- DK
- Denmark
- Prior art keywords
- risk
- predicting
- procedures
- hypertension
- methods
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000090 biomarker Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683956P | 2012-08-16 | 2012-08-16 | |
| PCT/US2013/055417 WO2014028875A1 (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2885641T3 true DK2885641T3 (da) | 2018-01-29 |
Family
ID=50100476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13830006.6T DK2885641T3 (da) | 2012-08-16 | 2013-08-16 | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9523696B2 (da) |
| EP (2) | EP2885641B1 (da) |
| JP (3) | JP6298466B2 (da) |
| CN (2) | CN104737023B (da) |
| AU (2) | AU2013302451B2 (da) |
| CA (1) | CA2882133A1 (da) |
| DK (1) | DK2885641T3 (da) |
| ES (1) | ES2656897T3 (da) |
| HK (3) | HK1250782A1 (da) |
| IN (1) | IN2015DN01259A (da) |
| MX (1) | MX358541B (da) |
| NO (1) | NO2983845T3 (da) |
| PL (1) | PL2885641T3 (da) |
| RU (2) | RU2683026C2 (da) |
| SG (2) | SG11201501200XA (da) |
| WO (1) | WO2014028875A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| EP3072978B1 (en) | 2002-05-09 | 2018-07-11 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
| ES2351623T3 (es) | 2006-04-24 | 2011-02-08 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de una enfermedad grave. |
| PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
| DK2827152T3 (da) | 2008-04-18 | 2016-09-12 | Critical Care Diagnostics Inc | Forudsigelse af risiko for større uønskede hjertehændelser |
| BR112012025728B1 (pt) | 2010-04-09 | 2022-01-11 | Critical Care Diagnostics, Inc | Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo |
| EP3605104B1 (en) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| WO2013012945A1 (en) | 2011-07-18 | 2013-01-24 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| CN109212223B (zh) | 2012-05-18 | 2021-11-12 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
| DK2885641T3 (da) | 2012-08-16 | 2018-01-29 | Critical Care Diagnostics Inc | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension |
| CN104737170A (zh) | 2012-08-21 | 2015-06-24 | 重症监护诊断股份有限公司 | 多标记风险分层 |
| ES2792227T3 (es) | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| RU2677611C1 (ru) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда |
| US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
| IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
| RU2767266C1 (ru) * | 2021-05-27 | 2022-03-17 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070817A1 (fr) * | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US7189518B2 (en) * | 2001-11-05 | 2007-03-13 | The Brigham And Women's Hospital, Inc. | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
| EP3072978B1 (en) | 2002-05-09 | 2018-07-11 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
| US20050123451A1 (en) | 2003-10-31 | 2005-06-09 | Hiroshi Nomura | System and apparatus for body fluid analysis using surface-textured optical materials |
| AU2005311601B2 (en) * | 2004-12-03 | 2011-12-01 | Rhode Island Hospital | Diagnosis and treatment of Alzheimer's Disease |
| ES2351623T3 (es) * | 2006-04-24 | 2011-02-08 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de una enfermedad grave. |
| US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
| HUE025058T2 (en) | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| WO2007130627A2 (en) * | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
| GB0703514D0 (en) * | 2007-02-23 | 2007-04-04 | Univ Ulster | Use of riboflavin |
| US20080300798A1 (en) * | 2007-04-16 | 2008-12-04 | Mcdevitt John T | Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics |
| EP2293076B1 (en) * | 2007-08-03 | 2012-12-19 | B.R.A.H.M.S GmbH | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease |
| DK2827152T3 (da) | 2008-04-18 | 2016-09-12 | Critical Care Diagnostics Inc | Forudsigelse af risiko for større uønskede hjertehændelser |
| JP5711131B2 (ja) * | 2008-10-07 | 2015-04-30 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 最初の有害事象の予測のためのバイオマーカー |
| CN102472752B (zh) * | 2009-08-28 | 2015-08-19 | B.R.A.H.M.S有限公司 | 用于不良事件的预后的降钙素原 |
| BR112012025728B1 (pt) | 2010-04-09 | 2022-01-11 | Critical Care Diagnostics, Inc | Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo |
| GB201013151D0 (en) * | 2010-08-04 | 2010-09-22 | Isis Innovation | Diagnostic method |
| EP3605104B1 (en) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| WO2013012945A1 (en) | 2011-07-18 | 2013-01-24 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| US20130157290A1 (en) * | 2011-12-16 | 2013-06-20 | Yves Levy | Soluble st2 as a marker for disease |
| CN109212223B (zh) | 2012-05-18 | 2021-11-12 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
| DK2885641T3 (da) | 2012-08-16 | 2018-01-29 | Critical Care Diagnostics Inc | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension |
| CN104737170A (zh) | 2012-08-21 | 2015-06-24 | 重症监护诊断股份有限公司 | 多标记风险分层 |
| CA2935958A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800333S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2013
- 2013-08-16 DK DK13830006.6T patent/DK2885641T3/da active
- 2013-08-16 MX MX2015002061A patent/MX358541B/es active IP Right Grant
- 2013-08-16 RU RU2015108959A patent/RU2683026C2/ru active
- 2013-08-16 EP EP13830006.6A patent/EP2885641B1/en not_active Not-in-force
- 2013-08-16 ES ES13830006.6T patent/ES2656897T3/es active Active
- 2013-08-16 US US13/969,116 patent/US9523696B2/en active Active
- 2013-08-16 CN CN201380052763.4A patent/CN104737023B/zh not_active Expired - Fee Related
- 2013-08-16 CA CA2882133A patent/CA2882133A1/en not_active Abandoned
- 2013-08-16 EP EP17191053.2A patent/EP3282258A1/en not_active Withdrawn
- 2013-08-16 PL PL13830006T patent/PL2885641T3/pl unknown
- 2013-08-16 SG SG11201501200XA patent/SG11201501200XA/en unknown
- 2013-08-16 SG SG10201704311VA patent/SG10201704311VA/en unknown
- 2013-08-16 AU AU2013302451A patent/AU2013302451B2/en not_active Ceased
- 2013-08-16 RU RU2019107598A patent/RU2019107598A/ru unknown
- 2013-08-16 JP JP2015527668A patent/JP6298466B2/ja not_active Expired - Fee Related
- 2013-08-16 CN CN201710532173.1A patent/CN107478841A/zh active Pending
- 2013-08-16 WO PCT/US2013/055417 patent/WO2014028875A1/en active Application Filing
-
2014
- 2014-04-10 NO NO14716337A patent/NO2983845T3/no unknown
-
2015
- 2015-02-16 IN IN1259DEN2015 patent/IN2015DN01259A/en unknown
- 2015-09-08 HK HK18110132.8A patent/HK1250782A1/zh unknown
- 2015-09-08 HK HK15108725.8A patent/HK1208075A1/xx not_active IP Right Cessation
- 2015-12-23 HK HK15112622.4A patent/HK1212022A1/xx not_active IP Right Cessation
-
2016
- 2016-12-19 US US15/382,810 patent/US10041957B2/en not_active Expired - Fee Related
-
2018
- 2018-02-23 JP JP2018030232A patent/JP6757757B2/ja not_active Expired - Fee Related
- 2018-08-03 US US16/054,378 patent/US20180335437A1/en not_active Abandoned
-
2019
- 2019-04-15 AU AU2019202597A patent/AU2019202597A1/en not_active Abandoned
-
2020
- 2020-08-31 JP JP2020145790A patent/JP2020196757A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2885641T3 (da) | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension | |
| EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
| WO2013066369A3 (en) | Methods for detecting graft-versus-host disease | |
| EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| WO2012115820A3 (en) | Biomarker panels, diagnostic methods and test kits for ovarian cancer | |
| WO2012166899A3 (en) | Biomarkers for predicting and assessing responsiveness to lenvatinib compounds | |
| WO2013087887A3 (en) | Biomarkers and parameters for preeclampsia | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| NZ606725A (en) | Methods for predicting anti-cancer response | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| WO2013096822A3 (en) | Test device for optical and electrochemical assays | |
| EA201890925A2 (ru) | Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы | |
| BR112012030587A2 (pt) | métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador | |
| BR112013008602A2 (pt) | dispositivo imunocromatográfico, método para a determinação de um carreador gênico, método para o diagnóstico, dispositivo para ensaio imunológico, método para a detecção e determinação da presença de uma proteína e kit | |
| EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
| EA201492284A1 (ru) | Применение маркеров в диагностике и лечении рака предстательной железы | |
| MX357429B (es) | Predictores para el tratamiento del cáncer. | |
| WO2013028807A3 (en) | Renal cell carcinoma biomarkers and uses thereof | |
| WO2014187884A3 (en) | Mirnas as non-invasive biomarkers for heart failure | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| EA201171239A1 (ru) | Способ детекции типа паппиломавируса человека (hpv) | |
| MX2013002652A (es) | Metodos y equipos para la deteccion de una infeccion en sujetos con bajos niveles de anticuerpos especificos. | |
| BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia |